A share price of Enfusion Inc [ENFN] is currently trading at $10.60, up 0.09%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ENFN shares have lost -4.93% over the last week, with a monthly amount drifted -5.61%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Goldman downgraded its rating to Sell on February 28, 2024, and dropped its price target to $8. On January 30, 2024, downgrade downgraded it’s rating to Underweight and revised its price target to $9 on the stock. UBS started tracking the stock assigning a Neutral rating and suggested a price target of $9 on November 07, 2023. Piper Sandler initiated its recommendation with a Neutral and recommended $11 as its price target on April 03, 2023. JP Morgan started tracking with a Neutral rating for this stock on March 15, 2023, and assigned it a price target of $12. In a note dated January 04, 2023, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $15 to $10.
Enfusion Inc experienced fluctuations in its stock price throughout the past year between $7.83 and $11.80. Enfusion Inc [NYSE: ENFN] shares were valued at $10.60 at the most recent close of the market.
Analyzing the ENFN fundamentals
Trailing Twelve Months sales for Enfusion Inc [NYSE:ENFN] were 201.61M which represents 13.88% growth. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at 0.04%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.04 and Total Capital is 0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.29 points at the first support level, and at 9.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.83, and for the 2nd resistance point, it is at 11.07.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Enfusion Inc [NYSE:ENFN] is 3.42. In addition, the Quick Ratio stands at 3.42 and the Cash Ratio stands at 1.99. Considering the valuation of this stock, the price to sales ratio is 6.78, the price to book ratio is 13.70 and price to earnings (TTM) ratio is 519.61.
Transactions by insiders
Recent insider trading involved Bastone Bronwen, Chief People Officer, that happened on Mar 05 ’25 when 3126.0 shares were sold. General Counsel, Campobasso Matthew completed a deal on Mar 05 ’25 to sell 1695.0 shares. Meanwhile, Chief Executive Officer Movchan Oleg sold 11452.0 shares on Mar 06 ’25.
